DDInter1021 DDInter1435
Lanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome. This drug is a long-acting analog of the drug somatostatin, a growth hormone inhibitor. Lanreotide is manufactured by the company, _Ipsen Pharmaceuticals_ as lanreotide acetate, and marketed as _Somatuline_. It is approved in several countries worldwide, including the United Kingdom, Australia, and Canada. Lanreotide was first approved for use in the United States by the FDA on August 30, 2007.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Lanreotide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Lanreotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bromocriptine
Lanreotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lurasidone
Lanreotide {u} may lead to a major life threatening interaction when taken with {v} Lonafarnib
Lanreotide {u} may lead to a major life threatening interaction when taken with {v} Copper oxodotreotide Cu-64
Lanreotide may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Lanreotide may cause a moderate interaction that could exacerbate diseases when taken with Bromocriptine
Lanreotide may cause a moderate interaction that could exacerbate diseases when taken with Lurasidone
Lanreotide may lead to a major life threatening interaction when taken with Lonafarnib
Lanreotide may lead to a major life threatening interaction when taken with Copper oxodotreotide Cu-64